Exhibit 10.3





Exhibit 10.3




THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED,
HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER
THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT
REGISTRATION IS NOT REQUIRED UNDER SUCH ACT OR UNLESS SOLD PURSUANT TO RULE 144 UNDER SUCH ACT.



			
	 	 	 
	Date of Issuance
	 	Void after
	July 15, 2011
	 	July 15, 2012






BIOMIMETIX PHARMACEUTICAL, INC.

WARRANT TO PURCHASE SHARES OF COMMON STOCK




This Warrant to Purchase Shares of Common Stock (this “Warrant”), is issued to Omni Bio
Pharmaceutical, Inc. or its permitted assigns (the “Holder”) by BioMimetix Pharmaceutical, Inc., a
Delaware corporation (the “Company”).



1. Purchase of Shares.




2. (a) Number of Shares. Subject to the terms and conditions set forth herein, the Holder
is entitled, upon surrender of this Warrant at the principal office of the Company (or at such
other place as the Company shall notify the Holder in writing), to purchase from the number of
shares of Common Stock such that the Subscriber will own a total of 40% of the issued and
outstanding capital stock of the Company on a Fully Diluted Basis following the exercise of the
Warrant and the payment of the full Exercise Price of $2,000,000 (the “Shares”). If the Warrant is
exercised in part, then the number of Shares to be owned by the Holder following such exercise
(including the number of shares of Common Stock of the Company purchased by the Holder as of the
date hereof) will be calculated based on the following ownership percentage of the Company on a
Fully Diluted Basis: (Exercise Price x 15%) + 25% $2,000,000



“Fully Diluted Basis” shall mean the assumption that all outstanding options, warrants or other
convertible securities or instruments or other rights to acquire Common Stock or any other existing
or future classes of capital stock have been exercised or converted, as applicable, in full,
regardless of whether any such options, warrants, convertible securities or instruments or other
rights are then vested or exercisable or convertible in accordance with their terms. For purposes
of clarity, the 250,000 shares of Common Stock issued to the Holder pursuant to that certain Stock
Purchase Agreement of even date herewith shall be included in the calculation of Holder’s equity
ownership in the Company.



(b) Exercise Price. The purchase price for all of the Shares issuable pursuant to this
Section 1 shall be $2,000,000.00 if the Warrant is exercised in whole or such lesser amount as
determined by the Holder if the Warrant is exercised in part. Such purchase price, as adjusted
from time to time, is herein referred to as the “Exercise Price.”



Exercise Period. This Warrant shall be exercisable, in whole or in part, during the term
commencing on the date hereof and ending at 5:00 p.m. Eastern Time on July 15, 2012 (the “Exercise
Period”).


 


 









 





3. Method of Exercise.




(a) While this Warrant remains outstanding and exercisable in accordance with Section 2 above, the
Holder may exercise, in whole or in part, the purchase rights evidenced hereby. Such exercise
shall be effected by:



(i) the surrender of the Warrant, together with a duly executed copy of the Notice of Exercise
attached hereto, to the Secretary of the Company at its principal office (or at such other place as
the Company shall notify the Holder in writing); and



(ii) the payment to the Company of $2,000,000.00 if the Warrant is exercised in whole or such
lesser amount determined by the Holder if the Warrant is exercised in part.



(b) Each exercise of this Warrant shall be deemed to have been effected immediately prior to the
close of business on the day on which this Warrant is surrendered to the Company as provided in
Section 3(a) above. At such time, the person or persons in whose name or names any certificate for
the Shares shall be issuable upon such exercise as provided in Section 3(c) below shall be deemed
to have become the holder or holders of record of the Shares represented by such certificate.



(c) As soon as practicable after the exercise of this Warrant in whole or in part the Company at
its expense will cause to be issued in the name of, and delivered to, the Holder, or as such Holder
(upon payment by such Holder of any applicable transfer taxes) may direct:



(i) a certificate or certificates for the number of Shares to which such Holder shall be
entitled, and



(ii) in case such exercise is in part only, a new warrant or warrants (dated the date hereof)
of like tenor, calling in the aggregate on the face or faces thereof for the number of Shares equal
to the number of such Shares called for on the face of this Warrant minus the number of Shares
purchased by the Holder upon all exercises made in accordance with Section 3(a) above.



4. Covenants of the Company.




(a) Covenants as to Shares. The Company covenants and agrees that all Shares that may be
issued upon the exercise of the rights represented by this Warrant will, upon issuance in
accordance with the terms hereof, be validly issued and outstanding, fully paid and nonassessable,
and free from all taxes, liens and charges with respect to the issuance thereof.



(b) No Impairment. Except and to the extent waived or consented to by the Holder, or as
otherwise permitted under the terms hereof the Company will not, by amendment of the Certificate of
Incorporation or through any reorganization, transfer of assets, consolidation, merger,
dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the
observance or performance of any of the terms to be observed or performed hereunder by the Company,
but will at all times in good faith assist in the carrying out of all the provisions of this
Warrant and in the taking of all such action as may be necessary or appropriate in order to protect
the exercise rights of the Holder against impairment. During the term of this Warrant, the Company
will not issue any warrant with terms similar to the terms of this Warrant and will not authorize
or issue any capital stock with rights or preferences superior to those of the Common Stock.



(c) Reservation of Shares. A sufficient number of shares of Common Stock shall be reserved
at all time by the Company in order to effect the exercise of this Warrant, and the Company
promptly will take
all such corporate action as may, in the opinion of its counsel, be necessary to increase its
authorized but unissued Common Stock as shall be sufficient for such purpose.


 


2









 





5. No Fractional Shares or Scrip. No fractional shares or scrip representing fractional
shares shall be issued upon the exercise of this Warrant, but in lieu of such fractional shares the
Company shall make a cash payment therefor on the basis of the Exercise Price then in effect.



6. No Stockholder Rights. Prior to exercise of this Warrant, the Holder shall not be
entitled to any rights of a stockholder with respect to the Shares, including (without limitation)
the right to vote such Shares, receive dividends or other distributions thereon, exercise
preemptive rights or be notified of stockholder meetings, and except as otherwise provided in this
Warrant, such Holder shall not be entitled to any stockholder notice or other communication
concerning the business or affairs of the Company.



7. Governing Law. This Warrant hall be governed by and construed in accordance with the
General Corporation Law of the State of Delaware.



8. Successors and Assigns. The terms and provisions of this Warrant shall inure to the
benefit of, and be binding upon, the Company and the holders hereof and their respective successors
and assigns.



9. Titles and Subtitles. The titles and subtitles used in this Warrant are used for
convenience only and are not to be considered in construing or interpreting this Warrant.



10. Notices. All notices and other communications given or made pursuant hereto shall be
in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be
notified, (b) when sent by confirmed electronic mail or facsimile if sent during normal business
hours of the recipient, and if not so confirmed, then on the next business day, (c) five (5) days
after having been sent by registered or certified mail, return receipt requested, postage prepaid,
or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying next
day delivery, with written verification of receipt.



11. Severability. If any provision of this Warrant is held to be unenforceable under
applicable law, such provision shall be excluded from this Warrant and the balance of the Warrant
shall be interpreted as if such provision were so excluded and shall be enforceable in accordance
with its terms.


 


3









 





IN WITNESS WHEREOF, the Company has executed this Warrant effective as of the date first set
forth above.



	 	 	 	 	 
	 	BIOMIMETIX PHARMACEUTICAL, INC.

 	 
	 	By:  	 	 
	 	 	James D. Crapo, President 	 



BioMimetix, Pharmaceutical, Inc.

Warrant to Purchase Shares of Common Stock

- Signature Page -




 


 









 







NOTICE OF EXERCISE




Biomimetix Pharmaceutical, Inc.

Attention: President





The undersigned hereby elects to purchase, pursuant to the provisions of the Warrant, as
follows:




                     shares of Common Stock pursuant to the terms of the attached
Warrant, and tenders herewith payment in cash of $                    , together
with all applicable transfer taxes, if any.



	 	 	 	 	 
	 	HOLDER:

 	 
	Date:___________________ 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:	 	 
	 
	 	Address:	 
	 		 
	 		 



	 	 	 
	Name in which shares should be registered: